(PharmaNewsWire.Com, December 05, 2018 ) The liquid biopsy market is expected to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2017, growing at a CAGR of 23.4% during forecast period of 2017 to 2021. Technological advancements, increasing number of new cancer cases, availability of funding, growing awareness about liquid biopsy through conferences and government initiatives, and benefits of liquid biopsy over solid tumor biopsy are some of major factors driving growth of market.
Liquid biopsy market classified into hospital/physician laboratories, reference laboratories, academic and research centers and other end users. Other end-users segment includes public health laboratories, pathology laboratories, and small molecular laboratories. Detailed insights on upcoming technologies, research & development activities, and new product launches in liquid biopsy market.
Key Audience of This Market as Follows: Pharmaceutical Companies Biotechnology Companies Research Institutes Contract Research Organizations Research and Consulting Companies Liquid Biopsy Product Manufacturers and Distributors Hospitals and Diagnostics Centers Reference Laboratories Government and Public Laboratories
Based on cancer type, liquid biopsy market segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers (melanoma, bladder cancer, and ovarian cancer). Based on circulating biomarkers, the liquid biopsy market is segmented into circulating tumor DNA (ct DNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other biomarkers (circulating RNA and protein).
The liquid biopsy market is segmented based on cancer type, circulating biomarkers, products & services, end users, and regions. Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers (melanoma, bladder cancer, and ovarian cancer).
Premium Insights 1 Liquid Biopsy: Market Overview 2 Geographic Analysis: Liquid Biopsy Market, By Circulating Biomarker 3 Market Size, By End User, 4 Market Size, By Product, 5 Market Size, By Circulating Biomarker, 6 Geographical Snapshot of the Market
The report analyzes the liquid biopsy market and aims at estimating market size and future growth potential of this market based on various segments such as by product, circulating biomarker, clinical application, application, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Click now for more Details, Queries and Corporate Discount on this study Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Software), End User (Reference Laboratory, Research Centers) - Forecast to 2021 report @ http://www.reportsnreports.com/contacts/discount.aspx?name=631133 .
Geographical , the global liquid biopsy market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2022, North America is expected to dominate the market which can be attributed to the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals. The APAC region is expected to register the highest CAGR during the forecast period.
Lung cancer segment is expected to account for the largest share of liquid biopsy market primarily due to technological advancements and the growing demand for advanced diagnostic technologies among the large base of lung cancer patients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
